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Background/Aims: We investigated the treatment out-
comes and prognostic factors of hepatocellular carcinoma 
(HCC) with obstructive jaundice. Methods: Among 2,861 pa-
tients newly diagnosed with HCC between 2002 and 2011, 
a total of 63 patients who initially presented with obstructive 
jaundice were analyzed. Only four patients presented with 
resectable tumors and underwent curative resection. In the 
other patients who presented with unresectable tumors, 5, 
8, 9, and 18 patients received transarterial chemoemboli-
zation (TACE), chemotherapy, radiotherapy, and combined 
treatment, respectively. Both the clinical and the treatment 
factors that affect overall survival (OS) were analyzed. Re-
sults: The median OS was 4 months, and the 1-year OS rate 
was 23%. Patients who received treatment for HCC had a 
significantly improved OS rate compared with the patients 
who received supportive care only (1-year OS, 32% vs 0%; 
p<0.01). Responders to treatment showed a better OS than 
nonresponders (1-year OS, 52% vs 0%; p<0.01). TACE and 
radiotherapy resulted in relatively good treatment responses 
of 64% and 67%, respectively. In multivariate analyses, 
treatment of HCC (p=0.02) and the normalization of serum 
bilirubin by biliary drainage (p=0.02) were significantly favor-
able prognostic factors that affected the OS. Conclusions: 
Unresectable HCC with obstructive jaundice has a poor prog-
nosis. However, effective biliary drainage and treatment of 
HCC such as with TACE or radiotherapy improves survival. (Gut 
Liver 2014;8:526-535)
Key Words: Transarterial chemoembolization; Drug therapy; 
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INTRODUCTION
Jaundice is a common complication in patients with hepa-
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tocellular carcinoma (HCC), and is observed in 19% to 40% of 
patients at the time of diagnosis.1-3 The most frequent cause of 
jaundice associated with HCC is the hepatic insufficiency due 
to underlying liver cirrhosis or extensive hepatic parenchymal 
destruction due to a massive liver tumor.4 Obstructive jaundice 
caused by HCC is rare and associated with a poor prognosis. 
Obstructive jaundice, presented in 1% to 12% of patients with 
HCC,5 is caused by tumor invasion or blood clots in the biliary 
tract.6 Previous studies have shown that curative resection can 
improve survival.7-10 However, the prognosis for patients, who 
cannot undergo surgery, is dismal with the median survival of 
2 to 4 months.11,12 Thus, proper management for HCC with ob-
structive jaundice remains unclear, especially in patients with 
unresectable HCC. In this study, we analyzed the treatment out-
comes in patients with HCC accompanying obstructive jaundice 
due to bile duct tumor invasion treated by surgery, transarterial 
chemoembolization (TACE), radiotherapy, chemotherapy, or a 
combination of these treatments. In addition, we investigated 
predictive factors of survival in patients with HCC accompany-
ing obstructive jaundice for survival to identify the patients who 
require intensive treatments.
MATERIALS AND METHODS
1. Study population
Between 2002 and 2011, 5,086 consecutive patients with 
HCC were treated at Severance Hospital, Yonsei University Col-
lege of Medicine. Among these patients, 2,861 patients were 
newly diagnosed with HCC. Of these, 307 patients presented 
with jaundice at the time of diagnosis. Of these 307 patients, 63 
(2.2%), who presented with obstructive jaundice due to bile duct 
tumor invasion at the time of diagnosis, were analyzed in this 
study. The diagnosis of HCC was made based on the guidelines 
proposed by the Korea Liver Cancer Study Group.13 The clinical 
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characteristics and biochemical values of patients at the time of 
diagnosis were analyzed. These included the etiology of HCC, 
serum chemistry, the presence of ascites and hepatic encepha-
lopathy, Child-Pugh’s classification, and Barcelona Clinic Liver 
Cancer (BCLC) Stage.14 To distinguish obstructive jaundice from 
jaundice caused by hepatic insufficiency, serum γ-glutamyl 
transpeptidase (γ-GT) and the finding of bile duct dilation in 
imaging studies (dynamic computed tomography [CT], magnetic 
resonance imaging, or endoscopic retrograde cholangiopancrea-
tography [ERCP]) were evaluated. HCC was classified as nodular 
or diffuse-infiltrative HCC by following the classification of 
Yuki with some modifications.15 Tumor size was measured on 
CT images based on the longest diameter of the tumor. The 
Institutional Review Board of Yonsei University Health System 
approved this study.
2. Treatment
All patients were evaluated by a multidisciplinary team in-
cluding hepatobiliary surgeons, radiation oncologists, hepatolo-
gists, oncologists, and interventional radiologists at Yonsei Liver 
Cancer Special Clinic, and treatment was determined based on 
both patient and tumor characteristics (Fig. 1). After the diagno-
sis of HCC with obstructive jaundice, biliary drainage, either by 
percutaneous transhepatic biliary drainage (PTBD) or ERCP with 
biliary stenting, was performed in 56 patients. The other seven 
patients could not undergo biliary drainage due to ascites, a 
bleeding tendency, or multiple sites of obstruction in the biliary 
tract. Median time interval between biliary drainage and initia-
tion of treatment for HCC was 14 days (range, 1 to 43 days). 
Four patients who had surgically resectable tumors, Child-Pugh 
class A status, and the retention rate of indocyanine green at 
15 minutes after injection (ICG-R15) less than 25% underwent 
curative resection; segmental resection of the liver with cho-
ledochoduodenostomy for one patient, and hemihepatectomy 
for three patients. TACE was performed in 14 patients by infu-
sion of a mixture of 5 mL lipiodol (Guerbet, Aunay-sous-Bois, 
France) and 50 mg adriamycin and followed by subsequent 
embolization of feeding arteries by gelatin sponge particles. 
Among these 14 patients, six patients who presented portal 
vein tumor thrombosis (PVTT), received radiotherapy followed 
by TACE. Seventeen patients received chemotherapy, nine, six, 
and two patients received intra-arterial cisplantin, intra-arterial 
5-fluorouracil, and systemic chemotherapy, respectively. Intra-
arterial chemotherapy was performed using an implantable port 
system. Radiotherapy was conducted in 27 patients. All patients 
underwent CT simulation and were treated with 3-dimensional-
conformal radiotherapy (3D-CRT) planned by the AcQsim® or 
the Pinnacle3 system (Philips Healthcare, Andover, MA, USA). 
The median radiation dose was 45 Gy (range, 8.4 to 62 Gy), 
and the median dose per fraction was 1.8 Gy (range, 1.2 to 3.1 
Gy). Radiotherapy was delivered with megavoltage beams (6 
or 10 MV X-ray), and the planning target volumes included 
radiographically visible gross tumor with 2 to 3 cm margins to 
compensate for setup error and internal organ motion. Median 
Fig. 1. Treatment scheme according to the clinical characteristics of the patients.
HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; EBRT, external beam radiotherapy; iA, intra-arterial; CHT, chemotherapy.
528  Gut and Liver, Vol. 8, No. 5, September 2014
time of treatment sessions was 2, ranged from 1 to 9, and 1 
treatment session means 1 time of intra-arterial chemotherapy, 
1 time of TACE, 1 cycle of systemic chemotherapy, or overall 
planned course of radiotherapy.
3. Statistical analysis
Treatment response was evaluated 1 to 3 months after the 
completion of planned treatment, according to the modified Re-
sponse Evaluation Criteria in Solid Tumors (mRECIST).16 On the 
basis of mRECIST criteria, patients who showed complete and 
partial responses were classified as responders, and patients who 
showed stable or progressive disease were classified as nonre-
sponders. The primary endpoint was overall survival (OS), which 
was defined as the time from the date of diagnosis to date of 
death resulting from any cause, or it was measured at the date 
of the last follow-up visit for survivors. Differences in bio-
chemical values before and after treatment were analyzed using 
paired sample t-tests. Survival was evaluated using Kaplan-
Meier estimates, and the log-rank test was used to assess the 
equality of the survival function across the group. Significant 
variables on univariate analyses (log-rank test) were input into 
the multivariate analyses using Cox regression analysis. Statisti-
cal analyses were conducted using SPSS version 20 (SPSS Inc., 
Chicago, IL, USA). A p-value of less than 0.05 was considered 
statistically significant.
RESULTS
1. Patients’ characteristics
 Patients’ clinical characteristics according to the effectiveness 
of biliary drainage are summarized in Table 1, and the details of 
patients’ characteristics are follows. The median patient age was 
54 years (range, 34 to 79 years), and 81% of patients were male. 
Chronic hepatitis B virus infection was the most common etiol-
ogy (76%), followed by chronic hepatitis C virus infection (6%). 
Twenty-seven patients (43%) presented with nodular HCC, while 
the other 36 patients (57%) presented with diffuse-infiltrative 
HCC. Fifty-one patients (81%) had tumors larger than 5 cm, 
and 33 patients (52%) had biliary tract obstruction at common 
hepatic duct. Obstruction at single site of the biliary tract was 
observed in 38 patients (60%), and obstruction at multiple sites 
was observed in remaining 25 patients. PVTT was observed in 
37 patients (59%), and most PVTT was located in the main or 
first branch of the portal vein. Forty patients (64%) had multiple 
tumors, and 27 patients (43%) were categorized as Child-Pugh 
class B. Five (8%), 21 (33%), and 37 (59%) patients were BCLC 
stage A, B, and C, respectively. Patients who did not undergo 
successful biliary drainage showed higher frequencies of com-
mon hepatic duct obstruction and multiple tumors than patients 
who underwent successful biliary drainage.
Laboratory values of the patients are also shown in Table 
1. The median serum albumin level was 3.3 g/dL, and 39 pa-
tients (62%) had a serum albumin level lower than 3.5 g/dL. 
Prothrombin time was elevated by more than 1.2 INR in 25 
patients (40%). The median initial total bilirubin level was 7.9 
mg/dL (range, 2.1 to 28.5 mg/dL), and it decreased to 2.9 mg/
dL (range, 0.3 to 47.6 mg/dL) after treatments. Serum total 
bilirubin level decreased in 29 patients (46%) after biliary drain-
age or treatment of HCC, while it was elevated in 15 patients 
(24%). Median AFP level was 602 ng/mL (range, 1.4 to 83,000 
ng/mL), and was higher than 200 ng/mL in 36 patients (57%). 
Median protein induced by vitamin K absence or antagonist-II 
(PIVKA-II) level was 1,849 mAU/mL (range, 15 to 2,000 mAU/
mL) and serum PIVKA-II levels were elevated (>40 mAU/mL) in 
49 patients (78%). PIVKA-II values were significantly decreased 
after treatment, and a treatment-induced decrease in AFP or 
PIVKA-II level was noted in 29 patients (46%). In addition, AFP 
or PIVKA-II level decreased in 21 patients (21/27, 78%) who 
underwent radiotherapy, and in eight patients (8/17, 47%) who 
were treated using other treatment modalities. Total bilirubin 
and AFP levels were significantly lower in patients who un-
derwent successful biliary drainage compared with the patients 
who did not.
2. Survival
During the follow-up period, a total of 50 deaths (79%) oc-
curred; most patients died of jaundice-related complications 
such as hepatic failure (20 patients) or biliary sepsis (nine pa-
tients). For all patients, the median survival was 4 months, and 
the 1-year survival rate was 23% (Fig. 2A). Biliary drainages, 
including PTBD and ERCP with stenting, were performed in 
40 and 16 patients, respectively. Among these patients, nine 
and six patients who underwent PTBD and ERCP with stent-
ing, respectively, had normalized total bilirubin levels after 
biliary drainage; those cases were defined as having effective 
biliary drainage. Biliary drainage significantly improved the 
1-year survival rate (24% vs 0%, p=0.02) (Fig. 2B). In addition, 
the 1-year survival rate was not statistically different between 
patients who underwent PTBD and ERCP with stenting (21% vs 
35%, p=0.66). Cumulative OS according to treatment modality 
is shown in Fig. 2C. Treatment of HCC significantly improved 
the 1-year survival rates compared with supportive care only 
(22% vs 0%, p<0.01). None of the four patients who underwent 
curative resection died, resulting in a 1-year survival rate of 
100%. In the patients treated with nonsurgical treatment op-
tions including TACE, chemotherapy, radiotherapy, or combined 
treatment, the 1-year survival rates were not significantly dif-
ferent among treatment modalities. However, those patients 
who received nonsurgical treatment had an improved 1-year OS 
rate than patients who were treated by supportive care only (25% 
vs 0%, p<0.01).
3. Treatment responses
Forty-four patients who received treatment of HCC were 
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Table 1. Clinical and Laboratory Characteristics of the Patients
Characteristic Unsuccessful BD* (n=48) Sucessful BD (n=15) p-value
Age, yr 57 (39–79) 52 (34–73) 0.10
Male gender 41 (85) 10 (67) 0.14
Etiology
    HBV
    HCV
    Others
36 (75)
4 (8)
8 (17)
12 (80)
0
3 (20)
1.00
0.56
0.71
Tumor type
    Nodular
    Diffuse-infiltrative
19 (40)
29 (60)
8 (53)
7 (27)
0.38
Tumor size, cm
    ≤5
    >5
8 (17)
40 (83)
4 (27)
11 (73)
0.46
Site of biliary obstruction
    CHD
    1st branch of HD
    2nd branch of HD
29 (60)
8 (17)
11 (23)
4 (27)
8 (53)
3 (20)
0.04
0.01
1.00
Biliary obstruction
    Single site
    Multiple sites
38 (79)
20 (21)
10 (67)
5 (33)
0.76
PVTT
    None
    Main or first branch
    Second or third branch
20 (42)
26 (54)
2 (4)
6 (40)
8 (53)
1 (7)
1.00
1.00
0.56
Multiplicity of tumor
    Solitary
    Multiple
16 (33)
32 (67)
10 (67)
5 (33)
0.04
Child-Pugh Class at diagnosis
    A
    B
23 (48)
25 (52)
13 (87)
2 (13)
0.02
BCLC stage
    A
    B
    C
2 (4)
18 (38)
28 (58)
3 (20)
3 (20)
9 (60)
0.08
0.35
1.00
Albumin, g/dL 3.2 (2.2–5.5) 3.3 (2.7–4.7) 0.26
Prothrombin time, INR 1.13 (0.8–2.48) 1.14 (0.95–2.13) 0.51
γ-GT, IU/L 203 (25–787) 242 (42–929) 0.88
Alkaline phosphatase, IU/L 192.5 (80–970) 236 (65–566) 0.76
Total bilirubin, mg/dL
    Initial 
    Pretreatment
    Posttreatment
10.2 (2.2–28.5)
8.1 (2.6–27)
5.6 (1.2–47.6)
3.9 (2.1-15.5)
1.2 (0.2–1.9)
1.0 (0.3–6.7)
<0.01
<0.01
<0.01
AFP, ng/mL
    Pretreatment
    Posttreatment
701 (1.4–83,000)
351 (3.4–83,000)
48.1 (1.4–2,736)
10.8 (1.5–1,488)
<0.01
<0.04
PIVKA-II, mAU/mL†
    Pretreatment 
    Posttreatment
2,000 (22–2,000)
272 (10–2,000)
1,849 (15–2,000)
197 (10–2,000)
0.57
0.56
Data are presented as median (range) or number (%).
BD, biliary drainage; HBV, hepatitis B virus; HCV, hepatitis C virus; CHD, common hepatic duct; PVTT, portal vein tumor thrombosis; BCLC, Bar-
celona Clinic Liver Cancer; GT, glutamyl transpeptidase; AFP, α-fetoprotein; PIVKA, protein induced by vitamin K antagonist or absence.
*Patients who did not undergo biliary drainage were included in this group; †p<0.01 in paired sample t-test between pretreatment values and post-
treatment values.
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evaluated according to mRECIST criteria. Twenty-seven patients 
(61%) were classified as responders, and the other 17 patients 
were classified as nonresponders (Table 2). All patients who 
underwent surgery were classified as responders. Treatment 
response rates for the patients who received TACE, TACE com-
bined with radiotherapy, intra-arterial chemotherapy, combined 
chemoradiotherapy, and radiotherapy alone were 60%, 67%, 
25%, 67%, and 67%, respectively. Responders had an improved 
1-year OS compared with nonresponders (52% vs 0%, p<0.01) 
(Table 2, Fig. 2D). In addition, Child-Pugh class A patients who 
received radiotherapy showed an excellent response rate of 92% 
(data not shown).
4. Prognostic factors
To determine prognostic factors affecting OS, several vari-
ables related to clinical features and treatment modalities were 
evaluated by univariate and multivariate analyses. On univari-
ate analysis, diffuse-infiltrative tumor (p=0.01), the presence of 
PVTT on main or first branch of portal vein (p<0.01), multiple 
tumors (p<0.01), Child-Pugh class B (p=0.01), and prolonged 
prothrombin time (p<0.01) were significantly unfavorable prog-
nostic factors affecting OS. Treatment of HCC (p<0.01), curative 
resection (p<0.01), and effective biliary drainage (p<0.01) were 
significant prognostic factors improving OS, respectively. Mul-
tivariate analysis found treatment of HCC (p=0.02) and effective 
biliary drainage (p=0.02) were significantly favorable prognostic 
factors, respectively. These data are shown in Table 3.
DISCUSSION
We investigated the treatment outcomes and prognostic 
factors for overall survival in HCC patients with obstructive 
jaundice. The prognosis of patients with HCC accompany-
ing obstructive jaundice was very poor with a median OS of 4 
months. Nevertheless, treatment of HCC and biliary drainage 
significantly increased survivals in multivariate analysis (Table 
Fig. 2. Kaplan-Meier plot of (A) overall survival for all patients, (B) overall survival depending on the method of biliary drainage, (C) overall sur-
vival according to the treatment for hepatocellular carcinoma (HCC), (D) survival of the 44 patients who received treatment for HCC according to 
the modified Response Evaluation Criteria in Solid Tumors.
ERCP, endoscopic retrograde cholangiopancreatography; PTBD, percutaneous transhepatic biliary drainage.
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3). As a result, 11 patients survived for longer than 1 year. 
Among these patients, the lives of eight patients were prolonged 
by radiotherapy, TACE, chemotherapy, or combined treatment, 
despite the fact that none of these patients were eligible for cu-
rative resection (Table 4).
HCC with tumor invasion to the bile duct causing obstruc-
tive jaundice was classified as “icteric type hepatoma” by Lin 
et al.17 or “cholestatic type of HCC” by Kunio.18 In the present 
study, among a total of 2,861 patients in this study cohort, the 
frequency of patients with icteric type HCC was 2.2%. A previ-
ous study in Taiwan reported that the frequency of icteric HCC 
was 0.53%,19 while a Japanese study reported a frequency of 
9.3%.6 Another Japanese study reported that nine (1.66%) out of 
542 cases of HCC treated surgically had macroscopic bile duct 
thrombi.20 The differences in frequency of icteric HCC according 
to country or institution could result from differences in envi-
ronmental and genetic factors, the etiology of HCC, or study 
design. In the present study, we included the patients only who 
presented symptomatic obstructive jaundice, while the patients 
who had incidentally discovered bile duct invasion in surgical 
specimens were excluded.
Previous studies have shown that biliary drainage procedures, 
such as PTBD and ERCP with biliary stenting have a beneficial 
effect on survival in patients with HCC accompanying obstruc-
tive jaundice.21,22 Consistent with these previous studies, we 
showed that effective biliary drainage is an important factor for 
OS in multivariate analysis. In addition, prolonged prothrombin 
time, which indicates impaired liver function, exacerbated OS 
in univariate analysis (Table 3). Moreover, many patients with 
HCC accompanying obstructive jaundice at the time of diagno-
sis have preserved liver function, while jaundice due to disease 
progression or hepatic insufficiency is associated with impaired 
liver function.23,24 In this study, 36 patients (57%) presented the 
Child-Pugh class A at the time of diagnosis. As a result, early 
and effective biliary drainage might be essential to preserve 
patients’ liver function and improve survival. However, effective 
biliary drainage for patients with HCC accompanying obstruc-
tive jaundice is a challenging problem as many patients present 
with multiple sites of biliary obstruction and diffuse-infiltrative 
tumors. Hence, investigation and improvement of intervention 
techniques such as PTBD and ERCP with biliary stenting are re-
quired to enhance patients’ survival.
In the present study, those patients who underwent cura-
tive resection showed better survival than patients who could 
not undergo surgery (1-year OS, 100% vs. 17%, respectively, 
p<0.01) as reported in previous studies.7-10 However, most HCC 
patients with obstructive jaundice present with surgically un-
resectable tumors due to advanced stage or are medically in-
operable due to hepatic insufficiency caused by accompanying 
cholangitis.20,25 In the present study, 57% and 64% of patients 
presented diffuse-infiltrative and multiple tumors, respectively. 
In a previous autopsy-based study that investigated pathologic 
features of HCC with bile duct tumor invasion, 58% of cases 
had infiltrative tumors.6 Thus, curative resection is not appli-
cable in most patients with this type of HCC; therefore, nonsur-
gical treatments such as TACE, chemotherapy, and radiotherapy 
are also important to improve patients’ survival. Although the 
survival rate of patients who received nonsurgical treatment 
was poor with 1-year survival rate of 25%, those patients who 
received nonsurgical treatment including TACE, chemotherapy, 
radiotherapy, or combined treatment had a better 1-year OS 
than patients treated by supportive care only (25% vs 0%, 
p<0.01). Although nonsurgical treatment did not improve out-
comes in patients who could not receive effective biliary drain-
age, the 1-year survival rate of patients who received both ef-
fective biliary drainage and nonsurgical treatments improved to 
56%.
PVTT is one of the reliable indicators of a poor prognosis for 
patients with HCC and also an important parameter in the BCLC 
staging system.14,26 A previous study reported that PVTT in 88% 
of patients with icteric HCC;6 in the present study, 61% of pa-
Table 2. Overall Survival for the 44 Patients Who Received Treatment 
for Hepatocellular Carcinoma according to the mRECIST Response
Treatment
No. of 
patient (%)
1-Year 
survival, %
p-value*
All patients
    Responder
    Nonresponder
27 (61)
17 (39)
51.7
0
<0.01
Curative resection
    Responder
    Nonresponder
4 (100)
0 
100
0
NA
TACE
    Responder
    Nonresponder
3 (60)
2 (40)
33
0
0.04
TACE+Radiotherapy
    Responder
    Nonresponder
6 (67)
3 (33)
50
0
0.07
Intra-arterial chemotherapy
    Responder
    Nonresponder
2 (25)
6 (75)
100
0
0.10
Chemotherapy+Radiotherapy
    Responder
    Nonresponder
6 (67)
3 (33)
33
0
0.30
Radiotherapy alone
    Responder
    Nonresponder
6 (67)
3 (33)
33
0
0.41
mRECIST, modified Response Evaluation Criteria in Solid Tumors; 
NA, not applicable; TACE, transarterial chemoembolization.
*Log-rank test.
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Table 3. Prognostic Factors for Overall Survival
Variable
Univariate analysis Multivariate analysis
1-Year OS, % p-value* HR 95% CI p-value†
Age, yr
    ≤50 
    >50
25.2
20.4
0.84
Gender
    Male
    Female
23.8
16.7
0.42
Active HBV infection
    Yes
    No
37.0
19.6
0.91
Tumor type
    Diffuse infiltrative tumor
    Nodular tumor
10.3
39.3
0.01 1.13 0.56–2.26 0.74
Tumor size, cm
    ≤5
    >5
36.5
19.1
0.16
PVTT on main or 1st branch of PV
    Yes
    No
11.3
39.3
<0.01 1.72 0.79–3.73 0.17
Site of biliary obstruction
    CHD
    Below CHD
17.2
28.5
0.84
Multiplicity of tumor
    Solitary
    Multiple
46.4
6.4
<0.01 1.18 0.53–2.59 0.69
Child-Pugh class
    A 
    B
39.2
0
0.01 0.99 0.48–2.04 0.98
PT prolongation
    Yes
    No
0
38.7
<0.01 1.63 0.78–3.42 0.20
Treatment for HCC
    Yes
    No
32.1
0
<0.01 0.42 0.21–0.85 0.02
Curative resection of tumor
    Yes
    No
100
17.1
<0.01 <0.01 NA 0.97
TACE
    Yes
    No
26.8
21.0
0.99
Radiotherapy
    Yes
    No
26.9
18.4
0.30
Chemotherapy
    Yes
    No
22.2
21.7
0.20
Effective BD
    Yes
    No
58.2
8.8
<0.01 0.26 0.09–0.78 0.02
OS, overall survival; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; PVTT, portal vein tumor thrombosis; CHD, common hepatic 
duct; PT, prothrombin time; HCC, hepatocellular carcinoma; NA, not applicable; TACE, transarterial chemoembolization; BD, biliary drainage.
*Log-rank test; †Cox regression analysis.
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tients presented with PVTT. In addition, the presence of PVTT is 
generally considered to be a relative contraindication for TACE 
due to the potential risk of ischemic liver injury.27 Moreover, 
one study reported that PVTT in the first branches of the portal 
vein or portal trunk decreased quality of life and reduced the 
success rate of endoscopic biliary drainage in the patients with 
HCC accompanying obstructive jaundice.22 Therefore, PVTT 
could exacerbate the prognosis by preventing effective biliary 
drainage as well as further TACE treatment.
Previous studies reported that TACE could prolong the surviv-
als of patients with unresectable HCC accompanying obstructive 
jaundice.19,28 However, many patients with HCC accompany-
ing obstructive jaundice present with PVTT as described above, 
thus, the application of TACE could be limited in these patients. 
Recent studies showed that radiotherapy combined with TACE 
is an effective and safe treatment option for HCC with PVTT.29,30 
In the present study, 14 patients underwent TACE. Among these 
patients, three patients without PVTT and six patients with PVTT 
received radiotherapy followed by TACE. Both TACE alone and 
radiotherapy followed by TACE resulted in relatively good treat-
ment responses of 60% and 67%, respectively. As a result, two 
patients who received TACE alone and TACE combined with 
radiotherapy, respectively, survived for more than 1 year (Table 4). 
Consequently, TACE or radiotherapy followed by TACE could be 
effective treatment options for patients with HCC accompanying 
obstructive jaundice. Especially, radiotherapy followed by TACE 
may be a good treatment option when PVTT is present.
In the present study, a total of 27 patients received radio-
therapy at a median radiation dose of 45 Gy, and 21 patients 
completed radiotherapy as initially planned without significant 
radiation-associated toxicities. In addition, 17 patients who re-
ceived radiotherapy were categorized as BCLC stage 3. However, 
radiotherapy resulted in a relatively respectable response rate of 
67% and 1-year survival rate of 27% despite the advance stages 
of HCC in these patients. Moreover, nine patients who received 
effective biliary drainage and radiotherapy had relatively good 
survivals with a median survival of 39 months and a 1-year 
survival rate of 65%. Six patients who received radiotherapy 
alone and radiotherapy combined with TACE or chemotherapy, 
survived for longer than a year (Table 4). Thus, radiotherapy 
combined with TACE is a potential treatment option in patients 
with PVTT, and radiotherapy alone is a potential treatment op-
tion in patients who are not able to undergo surgery or TACE 
due to advanced stage HCC.
Hepatic toxicities related to treatments such as TACE, che-
motherapy, or radiotherapy can worsen patients’ cholangitis or 
hepatitis associated with obstructive jaundice. Therefore, the use 
of modulators of hepatic and biliary toxicity, such as amifos-
tine31 could help to improve patients’ survival; further studies 
of new therapeutic agents to reduce treatment-related toxicities 
and preserve patients’ liver function are therefore critical.
In conclusion, we evaluated treatment outcomes in patients 
with HCC accompanying obstructive jaundice due to bile duct 
tumor invasion, and investigated prognostic factors for overall 
survival. Although, the prognosis of HCC patient with obstruc-
tive jaundice is dismal, our data suggest that effective biliary 
drainage and treatment of HCC including surgery, TACE, and ra-
diotherapy can improve survival. Techniques to improve biliary 
drainage and preserve liver function from jaundice-associated 
toxicities are required to improve the prognosis of HCC patients 
Table 4. Clinical and Tumor Characteristics of Patients Who Survived Longer than 1 Year
Patient,
age/sex
Tumor Biochemical values
Treatment Outcome
Type Size, cm PVT
Initial 
T. bil
Post-Tx 
T. bil γ
-GT PT, INR
47/M DI 10 PV1 7.5 2.9 137 1.33 PTBD, 45 Gy EBRT with systemic CHT DOD at 12 mo
38/M DI 10 PV1 2.8 1.5 311 1.19 PTBD, 45 Gy EBRT DOD at 14 mo
76/F DI 5 No 9.7 5.6 660 0.96 ERCP with stenting, iA CHT Alive at 15 mo
52/M SN 5 PV1 15.5 0.6 261 1.04 PTBD, 54 Gy EBRT Alive at 16 mo
52/M SN 3 No 5.6 0.8 99 1.19 PTBD, curative resection Alive at 34 mo
34/M SN 4 PV2 2.5 0.3 184 1.00 ERCP with stenting, 45 Gy EBRT with TACE Alive at 39 mo
57/M DI 8 No 4.7 0.6 503 1.02 ERCP with stenting, 50 Gy EBRT with TACE DOD at 42 mo
45/M SN 9 No 9.9 1.0 929 1.05 PTBD, 42.4 Gy EBRT with concurrent iA CHT DOD at 51 mo
54/M SN 2.8 No 8.4 0.5 418 0.98 PTBD, curative resection Alive at 52 mo
47/F SN 5 No 2.6 0.5 42 0.95 ERCP with stenting, TACE Alive at 67 mo
62/M SN 6 No 26.2 3.8 755 0.81 PTBD, curative resection Alive at 79 mo
PVT, portal vein thrombosis; T. bil, total bilirubin; Post-Tx, posttreatment; γ-GT, γ-glutamyl transpeptidase; PT, prothrombin time; M, male; DI, 
diffuse infiltrative; PV1, first or main branch of portal vein; PTBD, percutaneous transhepatic biliary drainage; EBRT, external beam radiotherapy; 
CHT, chemotherapy; DOD, died of disease; F, female; ERCP, endoscopic retrograde cholangiopancreatography; iA, intra-arterial; PV2, second or 
third branch of portal vein; SN, single nodular; TACE, transarterial chemoembolization.
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